US007427638B2

(12) **United States Patent**
Muller et al.

(10) **Patent No.: US 7,427,638 B2**
(45) **Date of Patent: Sep. 23, 2008**

(54) **(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYL-AMINOISOINDOLINE-1,3-DIONE:, AND METHODS OF SYNTHESIS AND COMPOSITIONS THEREOF**

(75) Inventors: **George W. Muller**, Bridgewater, NJ (US); **Peter H. Schafer**, Somerset, NJ (US); **Hon-Wah Man**, Princeton, NJ (US); **Chuansheng Ge**, Belle Mead, NJ (US)

(73) Assignee: **Celgene Corporation**, Summit, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 446 days.

(21) Appl. No.: **11/106,142**

(22) Filed: **Apr. 13, 2005**

(65) **Prior Publication Data**

US 2005/0192336 A1 Sep. 1, 2005

Related U.S. Application Data

(62) Division of application No. 10/392,195, filed on Mar. 19, 2003, now Pat. No. 6,962,940.

(60) Provisional application No. 60/438,450, filed on Jan. 7, 2003, provisional application No. 60/366,515, filed on Mar. 20, 2002.

(51) **Int. Cl.**
A61K 31/40 (2006.01)

(52) **U.S. Cl.** **514/411**; 514/416; 514/417; 548/451; 548/472; 564/80

(58) **Field of Classification Search** 514/411, 514/416, 417; 548/451, 472; 564/80
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,031,450	A	4/1962	Fischer et al.
3,322,755	A	5/1967	Roch et al.
3,920,636	A	11/1975	Takahashi et al.
4,001,237	A	1/1977	Partyka et al.
4,001,238	A	1/1977	Partyka et al.
4,047,404	A	9/1977	Hayashi
4,060,615	A	11/1977	Matier et al.
4,101,548	A	7/1978	Crenshaw et al.
4,162,316	A	7/1979	Nishimura et al.
4,209,623	A	6/1980	Juby
4,880,810	A	11/1989	Lowe, III
4,885,301	A	12/1989	Coates
5,147,875	A	9/1992	Coates et al.
5,354,571	A	10/1994	Morikawa et al.
5,401,774	A	3/1995	Pamukcu et al.
5,439,895	A	8/1995	Lee et al.
5,488,055	A	1/1996	Kumar et al.
5,608,914	A	3/1997	Keesler
5,614,530	A	3/1997	Kumar et al.
5,614,627	A	3/1997	Takase et al.
5,658,940	A	8/1997	Muller et al.
5,698,579	A	12/1997	Muller
5,703,098	A	12/1997	Muller et al.
5,710,170	A	1/1998	Guay et al.
5,728,844	A	3/1998	Muller et al.
5,728,845	A	3/1998	Muller et al.
5,736,570	A	4/1998	Muller et al.
5,798,373	A	8/1998	Warrellow
5,801,195	A	9/1998	Muller et al.
5,849,770	A	12/1998	Head et al.
5,877,200	A	3/1999	Muller
5,891,896	A	4/1999	Warrellow et al.
6,011,050	A	1/2000	Muller et al.
6,020,339	A	2/2000	Perrier et al.
6,020,358	A	2/2000	Muller et al.
6,034,089	A	3/2000	Han et al.
6,046,221	A	4/2000	Muller et al.
6,069,156	A	5/2000	Oku et al.
6,162,830	A	12/2000	Connor et al.
6,166,041	A	12/2000	Cavalla et al.
6,177,471	B1	1/2001	Menander et al.
6,204,275	B1	3/2001	Friesen et al.
6,218,400	B1	4/2001	Daugan et al.
6,300,335	B1	10/2001	Campbell et al.
6,316,472	B1	11/2001	Frenette et al.
6,333,354	B1	12/2001	Schudt

FOREIGN PATENT DOCUMENTS

EP	0 347 146	6/1989
EP	0 349 239 A2	6/1989

(Continued)

OTHER PUBLICATIONS

Craven et al., 1969, CAS: 71:117431.*
Berge et al., Journal of Pharmaceutical Science, 1977, vol. 66, pp. 1-19.*
Bundgaard et al. publication, 1985, Design of prodrug, pp. 1-4.*
FDA's guidance for industry, 2000, pp. 1-20.*
Dredge et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-674.
Dredge et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," *Crit. Rev. Immunol.* 22(5-6):425-437.
Dredge et al., 2002, "Recent developments in antiangiogenic therapy," *Expert Opin. Biol. Ther.* 2(8):953-966.
Gee et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," *Cancer Res.* 63(23):8073-8078.

(Continued)

Primary Examiner—Rei-Tsang Shiao
(74) *Attorney, Agent, or Firm*—Jones Day

(57) **ABSTRACT**

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

13 Claims, 2 Drawing Sheets